Flosulide is an effective selective COX-2 inhibitor for the treatment of inflammatory diseases.

Flosulide completely suppresses mitotic activity of OSC-2 cells, whereas mitotic activity of OSC-1 cells remain unchanged.Flosulide (1 nM-100 μM) causes a concentration-dependent and finally complete inhibition of PGE2 production in the OSC-2 cell line, but with no effect on PG formation in the OSC-1 cells.

In normovolemic rats, flosulide increases renal plasma flow (RPF) and and glomerular filtration rate (GFR). In hypovolemic rats, flosulide (5-25 mg/kg) reduces RPF and GFR. Flosulide at 5 mg/kg reduces 6-keto-PGF1alpha whereas at 25 mg/kg and after indomethacin at 10 mg/kg a fall in 6-keto-PGF1alpha and TXB2 appeares[1]. Flosulide (0.75 mg/day) significantly reduces proteinuria as compared to aspirin treatment. Plasma protein and albumin levels are significantly lower in the aspirin-treated group than in flosulide-treated rats[3].